April W. Armstrong, MD, MPH

Armstrong spoke in an interview regarding several different sessions presented at the 2026 AAD meeting.

Armstrong’s interview highlights oral therapies in the psoriasis treatment space highlighted in her session at the 2026 AAD meeting.

At AAD, April W. Armstrong, MD, MPH, discussed recent innovations in the atopic dermatitis treatment space, highlighting long-term safety data and more.

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

This interview highlights new 12-month, real-world data on tralokinumab and its long-term efficacy in patients with skin of color who live with atopic dermatitis.

Panelists discuss the questions below in this video. Looking ahead, what are your hopes for the future of psoriasis care with targeted oral therapies like TYK2 inhibitors, and what final reflections do you have on their emerging role in clinical practice?

Panelists discuss the questions below in this video. What do we know about the therapeutic potential of TYK2 inhibition in psoriatic arthritis?

Panelists discuss the questions below in this video. ESK-001, another highly selective TYK2 inhibitor, has advanced into phase 3 trials in plaque psoriasis. How does its mechanism of action and emerging phase 2 data compare with deucravacitinib and zasocitinib, and what features might distinguish it within the TYK2 inhibitor class?

Panelists discuss the questions below in this video. How do you see emerging TYK2 inhibitors, such as zasocitinib and ESK-001, fitting into the psoriasis treatment landscape, if approved? Building on IMMpulse findings that earlier biologic use in moderate psoriasis can improve outcomes, what opportunities do you see for TYK2 inhibitors to be used earlier in appropriate patients?

What are your impressions of the Phase 2b data of zasocitinib in psoriasis, particularly in terms of Psoriasis Area and Severity Index (PASI) responses, dose-dependent effects, and tolerability? How do you see these results influencing your real-world patient selection?

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Closing insights on expanding dermatology’s leadership in CSU management and embracing innovation to enhance patient outcomes.

Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.

Explore the distinct role of TIC-2 in psoriasis and how selective inhibition offers targeted treatment advantages over traditional JAK inhibitors.

Amanda Armstrong, MD, MPH, predicts a move toward mechanism-based therapy selection and highlights biomarkers that could guide personalized treatment.

Discussion on factors such as comorbidities, adherence, and access that influence the choice between oral BTK inhibitors and injectable biologics.

Experts discuss the future of psoriasis treatment, highlighting the potential of oral therapies to enhance patient adherence and quality of life.

Explore the complexities of psoriasis treatment, including advanced therapies, mechanisms of action, and the potential of molecular testing for personalized care.

Strategies for counseling patients about biologic vs oral therapy, improving adherence, and addressing hesitancy or misconceptions.

Examination of REMIX-1 and REMIX-2 trial results demonstrating remibrutinib’s efficacy, durability, and potential for remission.

Panelists discuss how the treatment landscape for psoriasis continues to evolve, with oral agents expected to play an expanding role alongside biologics. Ongoing innovation in TYK2 inhibition and PDE4 modulation may yield even more effective and tolerable options, reshaping patient expectations for convenience and control. Panelists discuss how integration of real-world data and head-to-head comparisons will clarify positioning of oral therapies across disease severities. Future directions include exploring combination strategies and earlier oral intervention to delay or reduce biologic use. Panelists discuss how continued advancement in oral therapy represents a broader shift toward personalized, accessible psoriasis care that empowers patients and supports sustained disease control.

Panelists discuss how practical factors such as dosing, monitoring, and patient preference shape optimal use of oral psoriasis therapies.

Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.

Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.

Exploration of using tools such as UAS7 and DLQI to quantify disease severity, predict poor response, and guide timely therapy escalation.

Review of updated CSU treatment algorithms and the balance between standardized and individualized care approaches.

Panelists discuss how future oral therapy research should focus on studying younger pediatric populations, implementing early intervention strategies, and investigating whether newer oral agents can reduce the incidence of psoriatic arthritis development.

Panelists discuss how both oral agents exhibit reassuring long-term safety and tolerability that support continued use in diverse psoriasis populations.

Panelists discuss how deucravacitinib provides greater scalp and high-impact site clearance than apremilast, supporting more personalized psoriasis care.